5NX Stock Overview
A medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nexstim Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.66 |
| 52 Week High | €5.50 |
| 52 Week Low | €2.04 |
| Beta | 1.16 |
| 11 Month Change | -12.41% |
| 3 Month Change | 58.50% |
| 1 Year Change | 100.00% |
| 33 Year Change | 0.22% |
| 5 Year Change | -51.76% |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5NX | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.1% | 3.8% | 1.3% |
| 1Y | 100.0% | -6.6% | 7.9% |
Return vs Industry: 5NX exceeded the German Medical Equipment industry which returned -5.7% over the past year.
Return vs Market: 5NX exceeded the German Market which returned 7.2% over the past year.
Price Volatility
| 5NX volatility | |
|---|---|
| 5NX Average Weekly Movement | 7.9% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5NX's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5NX's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 39 | Mikko Karvinen | www.nexstim.com |
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company’s navigated transcranial magnetic stimulation (nTMS) technology utilizes 3D navigation for providing accurate and personalized targeting of the TMS to the specific areas of the brain. It also offers Navigated Brain Therapy system, a navigated brain therapy system for the treatment of major depressive disorder (MDD) and chronic neuropathic pain; and Navigated Brain Stimulation (NBS) system, a navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim Plc Fundamentals Summary
| 5NX fundamental statistics | |
|---|---|
| Market cap | €32.47m |
| Earnings (TTM) | -€833.11k |
| Revenue (TTM) | €9.36m |
3.5x
P/S Ratio-39.0x
P/E RatioIs 5NX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5NX income statement (TTM) | |
|---|---|
| Revenue | €9.36m |
| Cost of Revenue | €1.66m |
| Gross Profit | €7.70m |
| Other Expenses | €8.53m |
| Earnings | -€833.11k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 82.23% |
| Net Profit Margin | -8.90% |
| Debt/Equity Ratio | 337.9% |
How did 5NX perform over the long term?
See historical performance and comparison